Arias-Badia, Marcel https://orcid.org/0000-0003-2270-0676
Pai, Chien-Chun Steven
Lwin, Yee May
Chen, PeiXi
Srinath, Aahir
Tanaka, Miho
Musser, Emily
Goodearl, Andrew
Gorman, Jacob V
Ritacco, Wendy
Fong, Lawrence
Clinical trials referenced in this document:
Documents that mention this clinical trial
Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockade
https://doi.org/10.1136/jitc-2024-010566
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
Documents that mention this clinical trial
Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockade
https://doi.org/10.1136/jitc-2024-010566
A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab.
https://doi.org/10.1200/jco.2024.42.16_suppl.2623
1074 PK/RO modeling of WTX-124, a tumor-activated IL-2 prodrug, highlights the potential for a substantially improved therapeutic index compared to other IL-2 molecules
https://doi.org/10.1136/jitc-2023-sitc2023.1074
Documents that mention this clinical trial
606 Pharmacodynamic activity of CX-801, a masked IFNα2b PROBODY® cytokine, in patients with advanced melanoma
https://doi.org/10.1136/jitc-2025-sitc2025.0606
Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockade
https://doi.org/10.1136/jitc-2024-010566
Funding for this research was provided by:
NIH (P30 DK063720, R35CA253175)
AbbVie (N/A)